COMP <GO>
MNKD vs AMPH // REVENUE GROWTH (YOY)
MannKind Corporation (NASDAQ) VS. Amphastar Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MNKD 3
— AMPH 7
▲ REVENUE GROWTH (YOY) LEADER: MNKD
LAST: $3.50 (+2.04%) • MKT CAP: $1.13B
revenue-growth
22.20%
LAST: $26.93 (+2.28%) • MKT CAP: $1.15B
revenue-growth
-1.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNKD VS. AMPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MNKD | AMPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.30% | 49.50% | +42.80 | MNKD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 54.50% | 9.00% | +45.50 | MNKD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 24.6x | 9.4x | +15.20 | AMPH | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 10.58% | -9.36 | AMPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | 19.50% | -8.40 | AMPH | /operating-margins <GO> |
| Net Profit Margin | 1.70% | 13.60% | -11.90 | AMPH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 22.20% | -1.70% | +23.90 | MNKD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 2.47 | -2.27 | AMPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.6 | 66.8 | -11.24 | AMPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.13B | $1.15B | -$20.1M | AMPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MNKD REV | AMPH REV | MNKD GROSS % | AMPH GROSS % | MNKD FCF | AMPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $349.0M | $719.9M | 92.3% | 49.5% | $13.7M | $121.2M |
| FY 2024 | $285.5M | $732.0M | 93.9% | 51.1% | $32.8M | $172.3M |
| FY 2023 | $199.0M | $644.4M | — | — | $34.1M | $183.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MNKD // BETA —
AMPH // BETA —